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Abstract: Irritable bowel syndrome (IBS) is a functional condition of the bowel that is diagnosed 
using clinical criteria. This paper discusses the nature of the diagnostic process for IBS and how 
this impacts epidemiological measurements. Depending on the diagnostic criteria employed, 
IBS affects around 11% of the population globally. Around 30% of people who experience the 
symptoms of IBS will consult physicians for their IBS symptoms. These people do not have 
significantly different abdominal symptoms to those who do not consult, but they do have greater 
levels of anxiety and lower quality of life. Internationally, there is a female predominance in 
the prevalence of IBS. There is 25% less IBS diagnosed in those over 50 years and there is 
no association with socioeconomic status. IBS aggregates within families and the genetic and 
sociological factors potentially underlying this are reviewed. Patients diagnosed with IBS are 
highly likely to have other functional disease and have more surgery than the general population. 
There is no evidence that IBS is associated with an increased mortality risk. The epidemiological 
evidence surrounding these aspects of the natural history is discussed.
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Introduction
The epidemiology of any condition is an expansive topic, covering many subjects that 
individually could warrant devoted review articles. Irritable bowel syndrome (IBS) is 
no different. The intention of this review is to provide a brief overview of the funda-
mental issues of epidemiological interest relating to IBS. We discuss the diagnostic 
process and variation in how IBS is defined, how many of the population have IBS 
based upon these definitions, which members of the population are most likely to be 
affected, and discuss key aspects of the natural history, including symptom fluctuation 
and the association with other functional conditions.
In compiling this review, potentially relevant articles were identified through a 
literature search using MEDLINE and Embase of English language papers  published 
since the first formal definition of IBS in 1978 until August 1, 2013. Medical  subject 
headings (MeSH) used were ‘irritable bowel syndrome’ or ‘IBS’ or ‘irritable colon’ 
or ‘functional bowel disease’ combined with ‘epidemiology’ or ‘incidence’ or 
 ‘prevalence’ or ‘natural history’ or ‘mortality’. The references of these papers were 
reviewed for additional important papers not initially captured.
What is IBS?
IBS is a chronic functional disorder of the gastrointestinal system. Patients experience 
abdominal pain and altered bowel habit, with either predominantly diarrhea (IBS-D), 
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constipation (IBS-C), or both (IBS-M). There is no definitive 
investigation as no biomarker has been found, so IBS is diag-
nosed clinically. The earliest reports describing IBS are from 
the turn of the 19th and 20th century.1 At this time, diagnosis 
was only made by exclusion of malignant, inflammatory, or 
infectious disease after full investigation and “extensive unsuc-
cessful surgeries.”2 IBS remained “frequently misdiagnosed 
and poorly understood”3 into the 1970s, with the problem of 
unsuccessful, or unnecessary, surgery continuing.3
In an attempt to standardize and define IBS and reduce 
unnecessary surgery, Manning created the first set of formal 
criteria that allowed IBS to be positively diagnosed without 
the need for extensive investigations to exclude other diagno-
ses. These criteria were developed through expert consensus 
to create the Rome criteria, now in their third iteration.4 The 
Rome criteria also recommend that IBS should be a positive 
diagnosis but are more restrictive than the Manning criteria. 
When assessing the epidemiology of IBS, the diagnostic 
criteria employed are important to consider as they reflect 
how cases are ascertained and the differences between studies 
and over time. Most studies use either the Manning, Rome 
II, or Rome III criteria, and the variation between these can 
be seen in Table 1. It is argued that the Rome criteria are 
only useful for clinical trials and not for clinical practice. 
The criteria have been compiled by secondary and tertiary 
care specialists who undoubtedly see a different population 
of patients than are seen in primary care where the criteria 
are recommended to be implemented. Clinicians frequently 
use other clinical findings (such as bloating and psychologi-
cal stress) to assist in diagnosing IBS and do not adhere to 
the criteria.5,6 Some even suggest that attempts to sub-type 
functional gastrointestinal disease are arbitrary and IBS 
should remain a diagnosis of exclusion.6–8 International best 
practice guidelines disagree with this stance and promote 
positive diagnosis using the Rome criteria.9
Table 1 Comparison of the Manning and Rome diagnostic criteria frequently used in epidemiological studies for case ascertainment
Manning (1978)12 Rome I (1989)13 Rome II (1999)14 Rome III (2006)4
2 or more of the following  
symptoms:
Abdominal distension
Pain relief with defecation
Frequent stools with pain
Looser stools with pain
Passage of mucus
Sensation of incomplete  
evacuation
At least 3 months of continuous  
or recurrent abdominal pain:
Relieved with defecation
or
Associated with change in stool consistency
with at least 2 of the following on at least  
25% of days:
Altered stool frequency
Altered stool form
Altered stool passage
Passage of mucus
Bloating or abdominal distension
At least 12 weeks in past 12 months  
of continuous or recurrent abdominal  
pain or discomfort
with at least 2 of the following:
Relief with defecation
Altered stool frequency
Altered stool form
Onset of symptoms more than  
12 months before diagnosis
At least 3 days per month in 
past 12 weeks of continuous 
or recurrent abdominal pain 
or discomfort
with at least 2 of the 
following:
Relief with defecation
Altered stool frequency
Altered stool form
Onset of symptoms more 
than 6 months before 
diagnosis
The validity of these diagnostic criteria has been studied; 
however, this has not been done using conventional mea-
surement of sensitivity and specificity in general population 
samples because there is no gold standard to allow indepen-
dent confirmation of diagnosis, such as a biomarker. Instead 
estimations of specificity have been made among those with 
organic gastrointestinal disease, and sensitivity amongst cases 
who have already presented and been diagnosed (potentially 
an atypical minority). All of these criteria have modest speci-
ficity to diagnose IBS in those with organic gastrointestinal 
disease of about 0.7.10 This reflects the fact that the symptoms 
experienced in IBS are common to other gastrointestinal 
conditions. Specificity is increased to 0.9 if patients with red 
flag symptoms such as anemia, weight loss, and rectal bleed-
ing (present in just 3% of patients)11 are more extensively 
investigated and IBS is diagnosed by exclusion.10 Sensitivity 
across the criteria ranges from 0.4 to 0.9 depending on the 
experience of the clinician,10 possibly reflecting variation in 
confidence to use criteria for positive diagnosis.
How much IBS is there?
As outlined above, there is no gold standard case definition of 
IBS. Diagnostic criteria have not been standardized over time 
and they have a large margin of error in their application.5,8,15 
The definition of cases in epidemiological studies is there-
fore difficult and there may be limited opportunities for 
ascertainment of cases. There is no specific or standardized 
therapy, with many of the preparations available over the 
counter and some patients not requiring any medication,15,16 
so prescription data have limited use. Few patients will 
be admitted to hospital with IBS or diagnosed during an 
admission,17 and IBS is not considered a cause of death so 
these data are also not useful to define cases. The methods 
chosen to define and ascertain cases will clearly affect the 
number of cases found.
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incidence
Symptoms associated with IBS are commonly experienced 
within the population, it has an insidious onset, and frequently 
does not result in medical care.16,18 Consequently, there is 
discrepancy between incidence of the first occurrence of 
symptoms, which occur within the community, and the first 
diagnosis of IBS, which will occur after visiting a physician.16 
Consequently, few studies calculate the incidence of IBS.
One study in the USA using first occurrence of IBS 
symptoms within the community estimated the incidence of 
new IBS by conducting two population cohort surveys 1 year 
apart. Of patients with no IBS symptoms and no diagnosis of 
IBS in the baseline survey, 9% had developed symptoms over 
the year, an incidence rate of 67 per 1,000 person-years.19 
Studies that opt for defining cases as first diagnosis by a 
physician produce more conservative estimates of around 
two per 1,000 person years.20–22
Global prevalence
Prevalence estimates for IBS vary greatly internationally, 
both within and between countries, as shown in Figure 1 
and Table 2.
Most studies addressing prevalence of IBS are community 
surveys, with the majority from Europe, Southeast Asia, and 
North America. Often, postal questionnaires or telephone inter-
views invite individuals to self-report symptoms, and these 
responses are then assessed by investigators  according to one 
set of diagnostic criteria. This method reflects the underlying 
burden of symptoms consistent with a diagnosis of IBS. Other 
studies ask participants if they have ever received a diagnosis 
of IBS, capturing those who have sought medical advice for 
their symptoms. The prevalence of IBS within the community 
is between 10% and 25%.20,43,44,57,58,62–65 Meta- analysis shows 
a pooled estimate of international IBS prevalence of 11.2% 
(95% confidence interval [CI] 9.8–12.8),38 with variation by 
geographic region; the lowest occurring in South Asia (7.0%) 
and the highest in South America (21.0%).38
Considerable heterogeneity exists between studies.38 Some 
of this is explained through the differences in study methodol-
ogy and sampling, as described above, and the use of different 
diagnostic criteria to define IBS, rather than a biological marker, 
may also account for some of the  variation. The Manning cri-
teria account for the highest reported prevalence,13,47 whilst the 
Rome iterations are associated with lower estimates of preva-
lence that are similar across the iterations.13 Meta-analysis has 
shown that prevalence does not vary significantly according to 
the calendar year in which studies are conducted.38
It is plausible that the underlying prevalence of symptoms 
in communities internationally is the same, around 11%, and 
the variations reflect differences in access to health care66,67 and 
acceptability of a diagnosis, both to the physician making the 
diagnosis and to the patient in receiving and believing it.5,68 
Significant stigma is associated with receiving a diagnosis of 
a functional disorder as well as seeking health care for IBS 
Prevalence
<10%
10% to <15%
15% to <20%
>20%
Figure 1 worldwide prevalence of irritable bowel syndrome, as reported by country.
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Table 2 Prevalence of irritable bowel syndrome reported 
internationally, the highest and lowest estimated rates for each 
country
Country Lowest  
estimated  
prevalence
95% CI Highest  
estimated  
prevalence
95% CI
France 1.123 NR 4.724 4.36–5.04
Thailand – – 5.725 NR
Netherlands – – 5.826 4.0–9.0
Hong Kong 3.727 2.0–5.2 6.628 NR
italy – – 7.229 6.0–9.0
iran – – 7.130 6.0–13.0
South Africa – – 8.131 NR
Norway – – 8.432 7.9–9.4
Bangladesh – – 8.533 7.0–10.0
Turkey 6.334 NR 10.235 6.0–16.0
Singapore 2.336 0.8–3.9 11.037 9.7–12.3
israel 2.938 NR 11.438 NR
People’s 
Republic of 
China
0.838 NR 11.539 NR
Germany – – 12.540 10.7–14.5
Australia 4.441 3.6–5.1 13.042 11.0–16.0
Pakistan – – 13.343 4.0–62.0
Canada – – 13.544 10.2–14.0
Japan 6.145 5.0–7.0 14.046 NR
Spain 3.347 2.1–4.9 14.147 10.0–18
Romania – – 14.438 11.9–19.0
Sweden 12.520 9.0–18.0 15.048 NR
South Korea 6.649 2.0–11.0 15.550 12.0–19.0
Malaysia – – 15.651 13.0–18.0
Finland 5.152 4.4–5.8 16.452 15.0–17.2
Brazil – – 17.053 12.0–23.0
New Zealand 3.354 2.1–4.5 18.854 16.3–21.3
Russia – – 19.038 17.0–22.0
Columbia – – 19.938 16.7–23.3
USA 3.055 NR 20.413 16.7–24.2
Taiwan 17.556 NR 22.156 NR
UK 6.157 NR 21.658 NR
Greece – – 21.459 NR
Peru 15.038 NR 24.038 21.0–28.0
Croatia – – 28.238 24.0–32.0
iceland 17.260 14.4–19.9 30.960 28.0–33.0
Nigeria – – 31.661 27.0–36.0
Abbreviations: CI, confidence interval; NR, not reported.
symptoms specifically.69,70 It is therefore likely that areas where 
greater stigma is perceived will report lower prevalence, as will 
populations where symptoms are more often identified as varia-
tions of normal. Those communities in which there is higher 
perceived stress or lower perceived quality of life, greater 
potential gain from receiving a diagnosis, or fewer barriers to 
accessing health care will report higher prevalence.71–74
Prevalence in primary care
Many patients do not seek medical attention for symptoms 
indicative of IBS.18 Estimates of the proportion who do 
attend primary care for their symptoms are between 10%63 
and 70%.75 In the UK, estimates of the proportion who con-
sult vary from 30%58 to 50%.57,62,63 Reported consultation 
rates of people with symptoms also vary in studies from 
Germany, between 10%63 and 50%.40 Asking individuals to 
recall if they have consulted a primary care physician about 
their symptoms shows that the proportion of patients who 
report they have attended primary care varies considerably 
by country across Europe. The highest proportion is in Italy, 
with 50% consulting; 30% consult in the Netherlands, 20% 
in Belgium, and 10% in Switzerland, France, and Spain.63 
These differences may again reflect differences in diagnostic 
criteria employed, perceived acceptability of symptoms, and 
ease of access to primary care, which varies across different 
health care systems. These studies are also limited by relying 
on individuals’ recall of their behavior. Studies from the USA 
report more consistently that 30% of people with symptoms 
will consult16,65 and, of these patients, 80% have IBS-D.16
There are no significant differences in gastrointestinal 
symptoms between those who consult and those who do 
not, but those who consult do report higher pain scores, 
greater levels of anxiety, and greater reduction in quality 
of life.76,77
Who gets IBS?
Sex
In most populations, women report more IBS symptoms than 
men, irrespective of the diagnostic criteria employed.68 Rates 
in women are approximately 1.5- to 3-fold higher than those 
seen in men.12,78,79 Internationally, the overall prevalence of 
IBS in women is 67% higher than in men (odds ratio 1.67 
[95% CI 1.53–1.82]). This relative difference reflects an 
absolute difference in prevalence of just over 5% between 
the sexes, with a prevalence in women of 14.0% (95% CI 
11.0–16.0) compared with 8.9% in men (95% CI 7.3–10.5).80 
In South Asia, South America, and Africa, rates of IBS in 
men are much closer to those of women, and in some cases 
higher. Consequently, if prevalence is stratified according to 
geographic region, no significant sex difference can be seen 
in these areas.80 It is possible that this reflects the sex differ-
ences in access to health care and symptom normalization 
in these regions.81,82 Equal proportions of men and women 
with symptoms seek primary care advice.83,84
It is likely that the differences in reported sex-specific 
prevalence occur for reasons similar to those discussed for 
overall prevalence. It is also probable that the rates reflect 
differences in illness behavior that motivates consulting and 
referral patterns rather than the underlying condition. It could 
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be argued that the high rate of IBS symptoms in people within 
the community who do not access health care is a measure 
of unmet need.68 However, it could also be considered that 
symptoms affecting such a high proportion of the population 
are a variation of normal function.
Age
IBS occurs in all age groups, including children85 and the 
elderly, with no difference seen in the frequency of sub-
types by age.86 However, 50% of patients with IBS report 
having first had symptoms before the age of 35 years,87 and 
prevalence is 25% lower in those aged over 50 years than in 
those who are younger.38 This would suggest that symptoms 
remit over time, and is contrary to the belief that IBS is a 
chronic lifelong condition, because, if this were the case, 
then prevalence should remain constant or increase with age. 
Patients aged over 50 years also report milder pain, but their 
overall quality of life is worse.86 Those aged over 65 years 
are also likely to have had their symptoms for longer than 
1 year before they consult, whilst those under 65 years report 
significantly shorter duration of symptoms.42
Socioeconomic status
One study suggested that IBS was associated with lower 
socioeconomic status,65 a finding supported by the theory that 
lower income is associated with poorer health care outcomes, 
lower overall quality of life, and increased life stressors.88 
However, others suggest that the opposite is true and that 
being in a higher socioeconomic group during childhood is 
associated with higher prevalence of IBS.89,90 Similarly, areas 
in which there is a lower proportion of people employed in 
manual labor have higher rates of IBS. It is suggested that 
this is due to the higher level of stress perceived by people 
working in professional and managerial roles.91 This supports 
the argument that IBS is a disease of industrialization and 
urbanization, and that the higher rates now being reported 
in Asia, South America, and Africa are due to increased 
affluence in these regions.92 This may be because those with 
higher income have greater access to health care and tendency 
to seek help and hence receive a diagnosis.93 It could also 
reflect differing dietary choices94 or greater internalization 
of stress in higher earning groups.95
Family studies
The relative risk of IBS is twice as high in individuals with 
a biological relative with IBS.96 In twin studies, having a 
mother or father with IBS is an independent risk factor for an 
individual having IBS and a stronger predictor than  having 
a twin with IBS.97 Concordance in monozygotic twins (the 
proportion of twin pairs who both have IBS) is less than 
20%,97,98 and the association seen in familial clustering is 
significantly reduced when somatization is adjusted for.99 
These findings suggest heredity may be more closely linked 
to learned behavior than to genetic factors.100
What is the natural history?
Misdiagnosis
At the time of diagnosis of IBS, rates of organic lesions found 
on colonoscopy in patients with no red flag symptoms are no 
higher than seen in healthy controls, ranging from around 
10%101,102 to around 40%.103,104 Even most patients with alarm 
symptoms have no organic pathology.105
In contrast to the endoscopy findings at diagnosis, in the 
period following diagnosis the rate of inflammatory bowel 
disease (IBD) is 9106 to 1621 times higher than the general 
population. The average time between diagnosis of IBS and 
IBD is 2–3 years,106,21 suggesting that, in some, IBS symptoms 
are possibly early signs of IBD before lesions are visible. 
Colorectal cancer incidence is around 1%21 in the first year fol-
lowing diagnosis of IBS, higher than in the general  population. 
After 1 year, the rate returns to the population level.
Symptom patterns
Symptoms experienced by patients with IBS fluctuate over 
time. Over short periods of time, as some patients experi-
ence resolution of symptoms, others develop new ones, 
meaning the prevalence of symptomatic IBS remains stable 
over 1–2 years follow-up.20,83,107 In the first 3 months fol-
lowing diagnosis, patients experience four distinct episodes 
of symptoms per month on average. The longest of these 
episodes lasts around 5 days, and most patients experi-
ence symptoms on more than half of the days.55 However, 
1 year after initial diagnosis 30%–45% of patients will have 
prolonged periods that are symptom free, potentially in 
remission.20,108 After 10 years, 50%–70% of patients report 
persistent symptoms.20,109
In patients who do report IBS symptom resolution, 45% 
will subsequently experience other functional gastrointestinal 
symptoms.20,110 Up to two-thirds of IBS patients experience 
functional dyspepsia, the prevalence of which in patients with 
IBS is up to seven times higher than in controls.111–113
If all gastrointestinal symptoms resolve, then many 
develop symptoms of other functional diseases.20,114 Those 
with lower quality of life and higher levels of anxiety 
are more likely to suffer with other functional comorbid 
conditions.111,115 Together with family studies proposing 
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consultation behavior is learnt and highly associated with 
somatization,97,99,116 this suggests that IBS is one expression 
of an underlying tendency toward functional disease.
Co-existing functional conditions
Fibromyalgia, chronic fatigue syndrome, chronic back pain, 
chronic pelvic pain, chronic headache, and temporoman-
dibular joint dysfunction exist in approximately half of all 
patients with IBS, and occur almost twice as often as in 
the general population.78,111,118 These conditions, defined by 
their symptoms, have considerable overlap and their eti-
ologies are poorly understood.119,120 Some people feel these 
conditions should be considered together under the single 
umbrella term of ‘functional somatic syndromes’.121 Whilst 
these conditions do share some predisposing risk factors, the 
triggers for developing each condition vary.120 Multivariate 
analysis supports the idea that somatic comorbidities seen 
in IBS are distinct disorders and not manifestations of one 
somatization disorder.118 Even so, patients who have IBS 
and other somatic comorbidities report more severe symp-
toms than those patients with IBS alone.111,115,122 In addition, 
over one-half of all patients with IBS report depression or 
anxiety,86,115,120,123 and these patients experience more severe 
somatic symptoms.124
Surgery
Symptoms of IBS have considerable overlap with organic 
gastrointestinal and pelvic pathologies. Consequently, 
patients with IBS are at risk of undergoing unnecessary sur-
gical procedures due to misdiagnosis.93,125 The likelihood of 
having cholecystectomy is between two126 and three127 times 
as high in IBS as in the general public, and patients with 
IBS are almost twice as likely to have appendectomies63,127 
or hysterectomies.127
Mortality
IBS is a functional disease that significantly reduces patients’ 
quality of life, is associated with depression and suicidal ide-
ation, and patients have an increased frequency of invasive 
procedures and surgery.118,127 Despite this, community-based 
studies have shown that IBS is not associated with any increased 
mortality.128,129 A large study in the USA of over 4,000 patients, 
followed for a total of 30,000 patient-years, and with 1,101 
deaths, observed no increased mortality compared with the 
general population (hazard rate 1.06 [95% CI 0.86–1.32]).128 
A recent much smaller study from the People’s Republic of 
China followed 263 patients over 5 years and found the same. 
They did notice that the incidence of  colorectal cancer was 
increased, especially in elderly patients with IBS-C, where 
it was 7.5 times that of the general population. This possibly 
reflects misdiagnosis or ascertainment bias.129
Summary
IBS is a significant health care burden, irrespective of setting or 
geography, affecting around 11% of the population globally.
Accurate case definition remains difficult in IBS due 
to the high frequency of symptoms within the community, 
variations in diagnostic criteria and the stringency with which 
they are implemented, lack of specific histopathological 
changes, and lack of a definitive point of onset. This makes 
epidemiological studies challenging, with rates dependent 
on the methods chosen to define and measure IBS, so the 
literature should be considered within this context.
Evidence of lower prevalence of IBS in older age groups 
suggests that symptoms resolve over time, but this is contra-
dicted by natural history studies, which imply chronicity of 
symptoms. A significant amount of evidence also suggests 
that patients with IBS are more likely to also have other 
functional conditions. Evidence suggests that ‘symptom shift-
ing’ occurs in a proportion of patients, where resolution of 
functional bowel symptoms sees development of functional 
symptoms in another system.
Older studies suggest a high secondary care burden of 
IBS, with it accounting for up to 50% of gastrointestinal 
outpatient clinic time. However, these are highly biased 
estimates, often reliant on questioning physicians about their 
perceived workload. More recent studies would suggest IBS 
accounts for closer to 20% of gastroenterology outpatient 
work, possibly in part reflecting changes in primary care 
referral guidelines. Even so, this remains a significant propor-
tion and highlights the importance of continuing to improve 
diagnosis and management of these individuals, to optimize 
their health care utilization and fully assess the impact and 
benefit of different management approaches.
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